245 related articles for article (PubMed ID: 18023356)
1. Immunotherapies for Hodgkin's lymphoma.
Kasamon YL; Ambinder RF
Crit Rev Oncol Hematol; 2008 May; 66(2):135-44. PubMed ID: 18023356
[TBL] [Abstract][Full Text] [Related]
2. Current treatment and immunotherapy of Hodgkin's lymphoma.
Klimm B; Schnell R; Diehl V; Engert A
Haematologica; 2005 Dec; 90(12):1680-92. PubMed ID: 16330443
[TBL] [Abstract][Full Text] [Related]
3. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model.
Renner C; Bauer S; Sahin U; Jung W; van Lier R; Jacobs G; Held G; Pfreundschuh M
Blood; 1996 Apr; 87(7):2930-7. PubMed ID: 8639913
[TBL] [Abstract][Full Text] [Related]
4. Adoptive immunotherapy for Hodgkin's lymphoma.
Kennedy-Nasser AA; Bollard CM; Rooney CM
Int J Hematol; 2006 Jun; 83(5):385-90. PubMed ID: 16787867
[TBL] [Abstract][Full Text] [Related]
5. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
[TBL] [Abstract][Full Text] [Related]
6. CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma.
Pohl C; Renner C; Schwonzen M; Schobert I; Liebenberg V; Jung W; Wolf J; Pfreundschuh M; Diehl V
Int J Cancer; 1993 May; 54(3):418-25. PubMed ID: 8389737
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
Bollard CM; Aguilar L; Straathof KC; Gahn B; Huls MH; Rousseau A; Sixbey J; Gresik MV; Carrum G; Hudson M; Dilloo D; Gee A; Brenner MK; Rooney CM; Heslop HE
J Exp Med; 2004 Dec; 200(12):1623-33. PubMed ID: 15611290
[TBL] [Abstract][Full Text] [Related]
8. High efficacy of combined rituximab and gemcitabine on Epstein-Barr virus-associated human B-cell lymphoma obtained after Hodgkin's xenograft in immunodeficient mice.
Decaudin D; Marszak FB; Couturier J; Mathiot C; Martin A; Némati F; Lantz O; Santo Jd; Arnaud P; Bordier V; Vincent-Salomon A; Poupon MF
Anticancer Drugs; 2006 Jul; 17(6):685-95. PubMed ID: 16917214
[TBL] [Abstract][Full Text] [Related]
9. Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies.
Renner C; Pfreundschuh M
J Hematother; 1995 Oct; 4(5):447-51. PubMed ID: 8581383
[TBL] [Abstract][Full Text] [Related]
10. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.
Roskrow MA; Suzuki N; Gan Yj; Sixbey JW; Ng CY; Kimbrough S; Hudson M; Brenner MK; Heslop HE; Rooney CM
Blood; 1998 Apr; 91(8):2925-34. PubMed ID: 9531603
[TBL] [Abstract][Full Text] [Related]
12. Novel antibodies in the treatment of non-Hodgkin's lymphoma.
Bhat SA; Czuczman MS
Neth J Med; 2009 Sep; 67(8):311-21. PubMed ID: 19767657
[TBL] [Abstract][Full Text] [Related]
13. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
Wagner HJ; Bollard CM; Vigouroux S; Huls MH; Anderson R; Prentice HG; Brenner MK; Heslop HE; Rooney CM
Cancer Gene Ther; 2004 Feb; 11(2):81-91. PubMed ID: 14685154
[TBL] [Abstract][Full Text] [Related]
14. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
[TBL] [Abstract][Full Text] [Related]
15. Current strategies of antibody-based treatment in Hodgkin's disease.
Schnell R; Borchmann P; Schulz H; Engert A
Ann Oncol; 2002; 13 Suppl 1():57-66. PubMed ID: 12078905
[TBL] [Abstract][Full Text] [Related]
16. Rituximab immunotherapy for non-Hodgkin's lymphoma.
White CA
Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
[TBL] [Abstract][Full Text] [Related]
17. [Elevated Epstein-Barr virus antibodies in patients with Hodgkin's disease].
Kuljić-Kapulica N
Srp Arh Celok Lek; 1998; 126(3-4):97-100. PubMed ID: 9863363
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease.
Grässer FA; Murray PG; Kremmer E; Klein K; Remberger K; Feiden W; Reynolds G; Niedobitek G; Young LS; Mueller-Lantzsch N
Blood; 1994 Dec; 84(11):3792-8. PubMed ID: 7949135
[TBL] [Abstract][Full Text] [Related]
19. Anti-idiotype vaccine against Hodgkin's lymphoma: induction of B- and T-cell immunity across species barriers against CD30 antigen by murine monoclonal internal image antibodies.
Pohl C; Renner C; Schwonzen M; Sieber M; Lorenz P; Pfreundschuh M; Diehl V
Int J Cancer; 1992 Apr; 50(6):958-67. PubMed ID: 1313400
[TBL] [Abstract][Full Text] [Related]
20. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.
Schnell R; Dietlein M; Staak JO; Borchmann P; Schomaecker K; Fischer T; Eschner W; Hansen H; Morschhauser F; Schicha H; Diehl V; Raubitschek A; Engert A
J Clin Oncol; 2005 Jul; 23(21):4669-78. PubMed ID: 16034043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]